The COVID-19 pandemic has flared across every part of the globe and affected populations
from different age groups differently. People aged from 40 to 80 years or older are at an …

The COVID-19 pandemic ignited research centered around the identification of robust
biomarkers and therapeutic targets. SARS-CoV-2, the virus responsible, hijacks the …

This study aimed to evaluate the efficacy of favipiravir (FPV) in preventing the development
of severe COVID-19 in patients with mild-to-moderate symptoms. The study evaluated 1037 …

The Avigan antiviral drug adsorption by an oxidized form of a graphene flake; so called
Ovalene, was investigated using density functional theory calculations to provide molecular …

Background The pharmacokinetics of oral favipiravir and the relationships of plasma
concentrations to antiviral effects are incompletely studied in influenza. Methods Serial …

Background While favipiravir had been the standard anti-SARS-CoV-3 drug for COVID-19
treatment in Thailand, the efficacy of favipiravir treatment is controversial. Andrographis …

This meta-analysis was conducted with the aim to assess the safety and efficacy of
favipiravir in treating patients with coronavirus disease 2019 (COVID-19). It was carried out …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …

We developed new iminosugar-based glycosidase inhibitors against SARS-CoV-2. Known
drugs (miglustat, migalastat, miglitol, and swainsonine) were chosen as lead compounds to …

Favipiravir (FVP) is a broad-spectrum antiviral that selectively inhibits viral RNA-dependent
RNA polymerase, first trialled for the treatment of influenza infection. It has been shown to be …